Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

The rigid walls of many corporations prevent collaboration—the critical step to building the connective tissue that allows the voices of innovation to be heard and embraced.

Read more about Junaid Bajwa, his experiences with digital health and technology in his day-to-day practice. Part of the Digital Healthcare Equation Series